Browse treatments

…e dysfunction. Emerging evidence suggests the potential role of human albumin infusion for the treatment of HE, but its optimal dosage remains undefin…

…f age) diagnosed within the past 8 weeks, with plans to receive chemotherapy, radiation or surgery.Primary and secondary outcome measures Pr…

…t the efficacy of therapies reliant on T-cell activity, such as PD-1 checkpoint blockade.1 Immune stimulatory agents interleukin-2 (IL-2) and the microb…

…hal gynecological cancer. Treatment typically involves surgery, chemotherapy, or both. However, 80% of ovarian cancer diagnoses are made in …

…Background Immunotherapy can prolong survival in a variety of cancers, including lung ca…

…-world cohort of older adults with stage III NSCLC treated with chemoradiation followed by durvalumab, treatment completion rates were low, an…

…entify early post-treatment changes potentially associated with immunotherapy-related cardiac effects.Methods Twenty-six healthy subjects underwent […

…b, and relatlimab/nivolumab. We included cases of SPL following ICI therapy for non-lymphoid malignancies. Duplicated reports, disease prog…

…atures from routine CT scans can be utilized to predict durable immunotherapy benefit in patients with advanced NSCLC, enhancing patient sele…

…nt chemoimmunotherapy (with anti-PD-1/PD-L1 and anti-CTLA4) and single agent chemoimmunotherapy (with anti-PD-1/PD-L1); however, direct comparisons of these re…

…tumours make triple negative breast cancer a good candidate for immunotherapy. We have developed small molecule cyclophilin inhibitors, which…

…nderscores AK135’s potential to improve the quality of life for chemotherapy patients through its anti-inflammatory mechanism.Abstract 1189 …